Life Extension Suggestions
Of critical importance to treatment-naïve patients is implementing as many of these ten critical steps as can safely be done concurrently with conventional therapy. In newly diagnosed patients who have not yet been treated, the objective is to eradicate the primary tumor and metastatic cells with a multi-pronged "first strike therapy" so that residual tumor cells are not given an opportunity to evolve survival mechanisms that make them resistant to further treatments. Omitting any of the following ten steps may provide an opening for residual cancer cells to mutate in a way that makes them very difficult to treat a second time.
Step One: Evaluating Tumor Cell Population
Make certain your surgeon sends a specimen of your tumor to Caris Life Sciences for immunohistochemistry testing. Be sure to follow the instructions that Caris Life Sciences provides for proper shipping of the surgical specimen. Contact information for Caris Life Sciences: Telephone: (888) 979-8669; Website: http://www.carislifesciences.com/oncology-molecular-intelligence
Step Two: Determine Sensitivity or Resistance to Chemotherapy
Contact Rational Therapeutics so that your surgeon can follow the precise instructions required to send a living specimen of your tumor for chemo- sensitivity testing. It is important that your surgeon carefully coordinate with Rational Therapeutics in order to ensure your cells arrive in a viable condition.
Contact information for Rational Therapeutics: Telephone: (562) 989-6455;
Step Three: Circulating Tumor Cell Testing
For a molecular analysis of your CTC contact the International Strategic Cancer Alliance at 610-628-3419 to arrange for a blood specimen to be obtained and shipped for CTC testing.
To test for the presence and quantity of CTC in your blood, speak with your physician regarding the Veridex CellSearch® CTC test. You may also order this test from Life Extension at 800-226-2370.
Step Four: Inhibiting the Cyclooxygenase Enzymes (COX-1 & COX-2)
- Take a low dose (81 mg) aspirin daily, and;
- Ask your physician to prescribe one of the following COX-2 inhibiting drugs:
- Lodine XL, 1000 mg once daily, or
- Celebrex, 100-200 mg every 12 hours
Note: The use of Lodine and Celebrex has been associated with an increased risk of heart attack and stroke. The anti-cancer benefits of these drugs have to be weighed against these increased cardiovascular risks. Using aspirin in combination with a COX-2 inhibitor may increase the risk for bleeding; speak with your physician before combining aspirin with a COX-2 inhibitor.
Step Five: Suppressing Ras Oncogene Expression
Ask your physician to prescribe one of the following statin drugs to inhibit the activity of Ras oncogenes:
- Mevacor (lovastatin)
- Zocor (simvastatin)
- Pravachol (pravastatin)
Note: Statin drugs may generate adverse side effects. Physician oversight and careful surveillance with monthly blood tests (at least initially) to evaluate liver function, muscle enzymes, and lipid levels are suggested.
In addition to statin drug therapy, consider supplementing with the following nutrients to further suppress the expression of Ras oncogenes:
- Curcumin: (as highly absorbed BCM-95® extract): 400 – 800 mg daily
- Note: Different curcumin formulations will differ in their absorption and bioavailability. These differences in absorption can affect the suggested doses. For example, one type of curcumin—called BCM-95—has been shown in studies to be approximately 7 times more bioavailable than traditional curcumin preparations (Antony 2008).
- Fish Oil: 2100 mg of EPA and 1,500 mg of DHA daily with meals
- Green Tea: 650 – 1300 mg of EGCG daily
- Aged Garlic Extract: 2400 mg daily with meals
- Vitamin E: 400 – 1000 IU of natural alpha tocopherol along with at least 200 mg of gamma tocopherol daily with meals
Step Six: Correcting Coagulation Abnormalities
Ascertain if you are in a hypercoagulable state by having your blood tested for prothrombin time (PT), partial thromboplastin time (PTT), and D-dimers. A hypercoagulable state is suggested if the shortening of the PT and PTT are seen. (see table on laboratory tests for hypercoagulability).
If there is any evidence of a hypercoagulable (prothrombotic) state, ask your physician to prescribe the appropriate individualized dose of low-molecular-weight heparin (LMWH). Repeat the prothrombin blood test every 2 weeks.
Also, refer to Life Extension’s Blood Clot Prevention protocol for more information.
Step Seven: Maintaining Bone Integrity
If you have a type of cancer with a proclivity to metastasize to the bone (i.e. breast or prostate), ask your physician for a bisphosphonate drug before evidence of bone metastasis occurs.
Because excessive bone breakdown releases growth factors into the bloodstream that can fuel cancer cell growth, the DPD urine test should be done every 60-90 days to detect bone loss. A QCT bone density scan should be done annually. The radiation exposure with QCT is only marginally greater than with DEXA scan. If either of these tests indicates bone loss, ask your physician to initiate bisphosphonate therapy and make sure you take plenty of bone building nutrients like vitamin K, calcium, magnesium, boron and vitamin D.
Note: The use of bisphosphonate drugs has been associated with an increased risk of osteonecrosis of the jaw. This risk is considerably greater in those who had major dental work performed during bisphosphonate use. Those using bisphosphonates should speak with their physician before undergoing major dental work. The use of bisphosphonate drugs has been associated with an increased risk of atrial fibrillation. The anti-cancer effects of these drugs have to be weighed against the increased risks of osteonecrosis of the jaw and atrial fibrillation.
Step Eight: Inhibiting Angiogenesis
There are clinical trials using anti-angiogenesis agents. Call (800) 422-6237 or log on to www.cancer.gov/clinicaltrials to find out if you are eligible to participate.
Several nutrients have demonstrated potential antiangiogenesis effects such as green tea extract and curcumin.
- Green tea; standardized extract: 725 – 1450 mg daily
- Curcumin (as highly absorbed BCM-95®): 400 – 800 mg daily
- Vitamin D: 5000 – 8000 IU daily (depending on blood levels)
- Grape extract (seed and skin): 150 – 300 mg daily
- N-Acetyl cysteine: 600 – 1200 mg daily
Step Nine: Inhibiting the 5-lipoxygenase (5-LOX) Enzyme
Decrease the consumption of saturated fats that contain high concentrations of arachidonic acid, such as meats, dairy products, and egg yolks.
Consider supplementing with the following nutrients to suppress 5-LOX enzyme activity:
- AprèsFlex™: 100 – 400 mg daily
- Fish Oil: 2100 mg of EPA and 1500 mg of DHA daily with meals
- Lycopene: 30 mg daily with meals
- Curcumin (as highly absorbed BCM-95®): 400 – 800 mg daily
Step Ten: Inhibiting Cancer Metastasis
The following three novel compounds have shown efficacy in inhibiting several mechanisms that contribute to cancer metastasis. It is especially important to consider these compounds during the perioperative period (period before and after surgery), because a known consequence of surgery is an enhanced proclivity for metastasis.
- Modified Citrus Pectin: 15 g daily, in three divided doses
- Cimetidine: 800 mg daily, in two divided doses
- Coriolus versicolor; standardized extract: 1200 – 3600 mg daily
Life Extension oncology health advisors are available to provide clarification on any of the steps in this protocol; they can be reached at 800-226-2370.
Disclaimer and Safety Information
This information (and any accompanying material) is not intended to replace the attention or advice of a physician or other qualified health care professional. Anyone who wishes to embark on any dietary, drug, exercise, or other lifestyle change intended to prevent or treat a specific disease or condition should first consult with and seek clearance from a physician or other qualified health care professional. Pregnant women in particular should seek the advice of a physician before using any protocol listed on this website. The protocols described on this website are for adults only, unless otherwise specified. Product labels may contain important safety information and the most recent product information provided by the product manufacturers should be carefully reviewed prior to use to verify the dose, administration, and contraindications. National, state, and local laws may vary regarding the use and application of many of the treatments discussed. The reader assumes the risk of any injuries. The authors and publishers, their affiliates and assigns are not liable for any injury and/or damage to persons arising from this protocol and expressly disclaim responsibility for any adverse effects resulting from the use of the information container herein.
The protocols raise many issues that are subject to change as new data emerge. None of our suggested protocol regimens can guarantee health benefits. The publisher has not performed independent verification of the data contained herein, and expressly disclaim responsibility for any error in literature.